RaymondLComenzoMD

Oncology • Boston, MA

Hematologic Oncology

Lecturer, Pathology, Tufts Medical Center

Join to view full profile

Dr. Comenzo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Comenzo's full profile

Already have an account?

Office
800 Washington St
Boston, MA 02111
Phone+1 617-636-5000

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Boston University Medical CenterResidency, Internal Medicine, 1986 - 1989
Boston University School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 1988 - 2025
NY State Medical License 1998 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Pathology Blood Banking/Transfusion Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Boston Magazine Castle Connolly, 2009-2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis Start of enrollment: 2002 May 01
Completed
Phase 2
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis Start of enrollment: 2015 Aug 01
Completed
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis Start of enrollment: 2017 Jan 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

19 citations
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
Robert F. Cornell, Anita D'Souza, Adetola A. Kassim, Luciano J. Costa, Racquel Innis-Shelton
Biology of Blood and Marrow Transplantation. 2017-02-01
392 citations
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari, Dan T Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew Yee
The New England Journal of Medicine. 2019-08-21
49 citations
Systemic immunoglobulin light-chain amyloidosis.
Raymond L. Comenzo
Clinical Lymphoma & Myeloma. 2006-11-01

Abstracts/Posters

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optim...
Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition
Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...
Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Untangling Amyloidosis 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Seeking AL Amyloidosis Very Early: The SAVE Trial - Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

What Is Causing the National Blood Shortage?March 4th, 2022
What Doctors Want You to Know About the Potential Link Between COVID-19 and Blood TypeJune 24th, 2020
Experimental Drug Shows Promise for Rare Genetic Disorder – WebMDFebruary 11th, 2019